The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the invention provide cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers of the invention include cellulose esters of formula (I) : wherein n of the ω-carboxyalkanoyl group, Formula (II), is 3, 4, 6, or 8 to provide a ω-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups and wherein R is chosen from : a hydrogen atom and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups wherein there is a total degree of substitution of the alkanoyl group and the ω-carboxyalkanoyl group of at least 2.0 and wherein the polymer comprises m repeating units where n = 1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone. Drugs that can be used in combination with such polymers include but are not limited to ritonavir, efavirenz, etravirine, celecoxib, clarithromycin, curcumin, ellagic acid, quercetin, naringenin, and resveratrol. Methods for making and using the compounds and compositions are also included within the scope of the invention.La présente invention concerne les domaines de la chimie et des produits pharmaceutiques. Des modes de réalisation de linvention concernent des esters de cellulose utiles pour inhiber la cristallisation en solution de médicaments. Des polymères spécifiques de linvention comprennent des esters de cellulose de formule (I) : dans laquelle n du groupe ω-carboxyalkanoyle, Formule (II), est 3, 4, 6 ou 8 pour fournir un groupe ω-carboxyalkanoyle choisi parmi les groupes succinoyle, glutaroyle, adipoyle, sébacyle et subéryle et dans laquelle R est choisi parmi : un atome dhydrogène
